BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan
· Delayed Price · Currency is TWD 35.50
-0.90 (-2.47%)
At close: Mar 9, 2026
BioGend Therapeutics Revenue
In the year 2025, BioGend Therapeutics had annual revenue of 222.34M TWD with 32.62% growth. BioGend Therapeutics had revenue of 60.49M in the quarter ending December 31, 2025, with 19.59% growth.
Revenue
222.34M
Revenue Growth
+32.62%
P/S Ratio
19.86
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 222.34M | 54.69M | 32.62% |
| Dec 31, 2024 | 167.65M | 57.74M | 52.53% |
| Dec 31, 2023 | 109.91M | 78.46M | 249.51% |
| Dec 31, 2022 | 31.45M | 22.18M | 239.26% |
| Dec 31, 2021 | 9.27M | 7.88M | 565.40% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Senhwa Biosciences | 1.08M |
| Medigen Biotechnology | 1.59B |
| Energenesis Biomedical CO.,LTD. | 7.46M |
| Formosa Pharmaceuticals | 12.16M |
| UnicoCell Biomed | 30.10M |
| Genovate Biotechnology | 492.41M |
| Pharmosa Biopharm | 136.72M |
| OBI Pharma | 49.29M |